208 related articles for article (PubMed ID: 25302649)
1. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
Veigel D; Wagner R; Stübiger G; Wuczkowski M; Filipits M; Horvat R; Benhamú B; López-Rodríguez ML; Leisser A; Valent P; Grusch M; Hegardt FG; García J; Serra D; Auersperg N; Colomer R; Grunt TW
Int J Cancer; 2015 May; 136(9):2078-90. PubMed ID: 25302649
[TBL] [Abstract][Full Text] [Related]
2. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
[TBL] [Abstract][Full Text] [Related]
3. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
Bauerschlag DO; Maass N; Leonhardt P; Verburg FA; Pecks U; Zeppernick F; Morgenroth A; Mottaghy FM; Tolba R; Meinhold-Heerlein I; Bräutigam K
J Transl Med; 2015 May; 13():146. PubMed ID: 25947066
[TBL] [Abstract][Full Text] [Related]
5. Expression and roles of fatty acid synthase in hepatocellular carcinoma.
Hao Q; Li T; Zhang X; Gao P; Qiao P; Li S; Geng Z
Oncol Rep; 2014 Dec; 32(6):2471-6. PubMed ID: 25231933
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells.
Deepa PR; Vandhana S; Krishnakumar S
Nutr Cancer; 2013; 65(2):311-6. PubMed ID: 23441619
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.
Uddin S; Hussain AR; Ahmed M; Abubaker J; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
Am J Gastroenterol; 2009 Jul; 104(7):1790-801. PubMed ID: 19491830
[TBL] [Abstract][Full Text] [Related]
10. Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer.
Grunt TW; Slany A; Semkova M; Colomer R; López-Rodríguez ML; Wuczkowski M; Wagner R; Gerner C; Stübiger G
Sci Rep; 2020 Sep; 10(1):14877. PubMed ID: 32913236
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
[TBL] [Abstract][Full Text] [Related]
12. Leucine deprivation inhibits proliferation and induces apoptosis of human breast cancer cells via fatty acid synthase.
Xiao F; Wang C; Yin H; Yu J; Chen S; Fang J; Guo F
Oncotarget; 2016 Sep; 7(39):63679-63689. PubMed ID: 27579768
[TBL] [Abstract][Full Text] [Related]
13. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
Mullen GE; Yet L
Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
[TBL] [Abstract][Full Text] [Related]
14. Resensitizing Paclitaxel-Resistant Ovarian Cancer via Targeting Lipid Metabolism Key Enzymes CPT1A, SCD and FASN.
Ma Q; Liu Z; Wang T; Zhao P; Liu M; Wang Y; Zhao W; Yuan Y; Li S
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003694
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
16. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer.
Cai Y; Wang J; Zhang L; Wu D; Yu D; Tian X; Liu J; Jiang X; Shen Y; Zhang L; Ren M; Huang P
Med Oncol; 2015 Jan; 32(1):391. PubMed ID: 25433947
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
18. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells.
Jiang L; Fang X; Wang H; Li D; Wang X
Front Immunol; 2018; 9():2927. PubMed ID: 30619288
[TBL] [Abstract][Full Text] [Related]
19. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
Int J Mol Med; 2008 Oct; 22(4):433-9. PubMed ID: 18813848
[TBL] [Abstract][Full Text] [Related]
20. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]